Neurocrine Biosciences (NBIX) News Today → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free NBIX Stock Alerts $134.97 +1.90 (+1.43%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 8 at 6:54 AM | marketbeat.com1832 Asset Management L.P. Buys New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)1832 Asset Management L.P. bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 41,000 shares of the company's stock, valued at appJune 7 at 5:25 AM | marketbeat.comAllianz Asset Management GmbH Sells 52,518 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Allianz Asset Management GmbH trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 63.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,608 shares of the company's stock aJune 7 at 2:52 AM | americanbankingnews.comAnalysts Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $150.85June 6 at 8:27 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stake Raised by First Trust Advisors LPFirst Trust Advisors LP boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 27.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 590,725 shares of the compaJune 5 at 11:53 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Armistice Capital LLCArmistice Capital LLC trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,048,000 shares of the company's stock afJune 5 at 2:34 AM | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Strong-Buy at StockNews.comJune 4, 2024 | marketbeat.comRhenman & Partners Asset Management AB Acquires 7,434 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Rhenman & Partners Asset Management AB grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 62,000 shares of the company's sJune 4, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty-five analysts that are covering the company, Marketbeat.com reports. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating anJune 3, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Upgraded to Strong-Buy at StockNews.comStockNews.com raised shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Monday.June 3, 2024 | marketbeat.comAPG Asset Management US Inc. Buys Shares of 18,534 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)APG Asset Management US Inc. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 18,534 shares of the companyJune 3, 2024 | prnewswire.comNeurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024June 3, 2024 | prnewswire.comNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineJune 3, 2024 | prnewswire.comNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineJune 2, 2024 | marketbeat.comHsbc Holdings PLC Acquires 25,975 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Hsbc Holdings PLC grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 33.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 103,956 shares of the company's stock after acquiring an additionalJune 2, 2024 | americanbankingnews.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 40,000 Shares of StockMay 31, 2024 | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $5,338,400.00 in StockMay 31, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Trading Down 5.3%May 31, 2024 | marketbeat.comNorges Bank Acquires New Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Norges Bank bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 271,182 shares of the company's stock, valued at approximately $35,731May 31, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Stock Rating Reaffirmed by WedbushMay 30, 2024 | marketbeat.comStephen A. Sherwin Sells 40,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Stephen A. Sherwin sold 40,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the sale, the director now owns 26,504 shares in the company, valued at $3,537,223.84. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.May 30, 2024 | marketbeat.comWeiss Asset Management LP Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Weiss Asset Management LP purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 14,496 shares of the company's stock, valued at approximately $1,May 29, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Neurocrine (NBIX)May 29, 2024 | prnewswire.comNeurocrine Biosciences to Participate at Investor Conferences in JuneMay 29, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 5.3%Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 5.3%May 29, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $193.00 by Analysts at UBS GroupMay 29, 2024 | markets.businessinsider.comNeurocrine Biosciences CEO Kevin Gorman To Retire; Appoints Kyle Gano As CEO-electMay 28, 2024 | marketwatch.comNeurocrine Biosciences Names Kyle Gano as Next CEOMay 28, 2024 | reuters.comNeurocrine founder-CEO Gorman to retire in OctoberMay 28, 2024 | prnewswire.comNeurocrine Biosciences Announces CEO Succession PlanMay 28, 2024 | markets.businessinsider.comKey Takeaways From Neurocrine Biosciences Analyst RatingsMay 28, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $193.00 at UBS GroupUBS Group raised their price target on shares of Neurocrine Biosciences from $174.00 to $193.00 and gave the stock a "buy" rating in a research note on Tuesday.May 28, 2024 | prnewswire.comNeurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024May 26, 2024 | marketbeat.comPrimecap Management Co. CA Purchases 6,738 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Primecap Management Co. CA raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 398,323 shares of the company's stock aftMay 25, 2024 | marketbeat.comWestfield Capital Management Co. LP Sells 54,855 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Westfield Capital Management Co. LP decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 594,437 shares of the company's stock after selling 54,855 shares during theMay 24, 2024 | marketbeat.comAssetmark Inc. Purchases 8,678 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Assetmark Inc. raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 30.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 36,955 shares of the company's stock after purchasing an additional 8,678 shares during the period. AssMay 23, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Clearbridge Investments LLCClearbridge Investments LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 9.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 340,802 shares ofMay 22, 2024 | marketbeat.comING Groep NV Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)ING Groep NV purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,300 shares of the company's stock, valued at approximatelyMay 22, 2024 | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Shalini Sharp Sells 1,106 SharesMay 21, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $156,941.40 in StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Shalini Sharp sold 1,106 shares of Neurocrine Biosciences stock in a transaction on Friday, May 17th. The stock was sold at an average price of $141.90, for a total transaction of $156,941.40. Following the completion of the sale, the director now owns 994 shares of the company's stock, valued at approximately $141,048.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.May 21, 2024 | prnewswire.comNeurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) CapsulesMay 21, 2024 | marketbeat.comTrexquant Investment LP Acquires 82,139 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Trexquant Investment LP lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1,364.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,160 sharesMay 20, 2024 | marketbeat.comGW&K Investment Management LLC Sells 18,829 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)GW&K Investment Management LLC lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 535,962 shaMay 19, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Has $14.40 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Robeco Institutional Asset Management B.V. cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 29.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 109,321 shares ofMay 18, 2024 | marketbeat.comBrown Advisory Inc. Raises Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Brown Advisory Inc. lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,113,413 shares of the company's stock after purchasinMay 18, 2024 | marketbeat.comFiera Capital Corp Raises Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Fiera Capital Corp boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 516,865 shares of the company's stock after acquiring an additional 5,497 sharMay 17, 2024 | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 12,500 Shares of StockMay 16, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $1,695,375.00 in StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Gary A. Lyons sold 12,500 shares of the company's stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $135.63, for a total value of $1,695,375.00. Following the completion of the transaction, the director now directly owns 116,947 shares of the company's stock, valued at approximately $15,861,521.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.May 16, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Principal Financial Group Inc.Principal Financial Group Inc. increased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 10.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 418,245 shares of the company's stock after purchasing anMay 15, 2024 | marketbeat.comM&G Investment Management Ltd. Acquires 5,781 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)M&G Investment Management Ltd. grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 73,615 shares of the company's stock after purchasing an additional 5,7May 14, 2024 | nasdaq.comEvercore ISI Group Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform Recommendation Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address We’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How) (Ad)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from these levels. But there are at least 10 different coins that I like even better. NBIX Media Mentions By Week NBIX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼1.030.73▲Average Medical News Sentiment NBIX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼149▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Bio-Techne News Today Qiagen News Today CRISPR Therapeutics News Today Denali Therapeutics News Today Adaptive Biotechnologies News Today Biogen News Today Alnylam Pharmaceuticals News Today BioMarin Pharmaceutical News Today Incyte News Today United Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored